ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Revenue of ProKidney Corp. (PROK)
Revenue in 2023 (TTM): $
According to ProKidney Corp.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of ProKidney Corp.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-3,169,000 | $-147,669,000 | $-129,451,000 | $-35,468,000 |
| 2022 | $ | $-3,036,000 | $-143,988,000 | $-147,239,000 | $-148,135,000 |
| 2021 | $ | $-1,984,000 | $-53,126,000 | $-55,108,000 | $-55,146,000 |
| 2020 | $ | $ | $-26,017,000 | $-26,981,000 | $-26,749,000 |
| 2019 | $ | $ | $-18,292,000 | $-79,254,000 | $-79,615,000 |